Key takeaway: Ind-Swift Laboratories Limited reported strong Q1 FY27 results, with operating income rising 21.16% year-on-year to ₹186.08 crore and operating EBITDA expanding 2.85x to ₹33.32 crore. The company highlighted growth in its export business, which contributed 57.20% of quarterly sales, up from 48% in Q1 FY26, driven by own-brand products and CDMO partnerships with Viatris, Manx, and Arrotex. New product launches, including Ibuprofen Sachet and Macrogol Sachet, and increased global registrations (850+) supported this growth. The company also noted a 1258 bps increase in operating EBITDA margin to 17.91% and a 827 bps rise in PAT margin to 13.26%. Management guided toward ₹1200 crore revenue by FY29, with CDMO revenue expected to grow to ₹635 crore by FY29 from ₹180 crore in FY27. Capex plans of ₹250 crore over 2.5 years were outlined, focusing on facility upgrades and warehouse expansion. The company emphasized its strategy of shifting toward high-margin own-brands and expanding regulatory presence, with no immediate plans to divest its Synthimed stake. Management also discussed R&D capabilities, ongoing partnerships, and product pipelines, including launches of Clarithromycin dry suspension and Esomeprazole in FY28.

Key takeaway: Ind-Swift Laboratories Limited reported strong financial results for Q1 FY27, with operating EBITDA increasing 2.85 times year-over-year to ₹33.32 crore and an EBITDA margin expansion of 1,258 basis points to 17.91%. Standalone operating income grew 21.16% year-over-year to ₹186.08 crore, while profit after tax (PAT), excluding exceptional items, rose 2.04 times to ₹24.68 crore, with a PAT margin improvement of 827 basis points to 13.26%. The company commercialized partnerships with Viatris, Manx, and Arrotex, contributing an incremental revenue of ₹200-220 crore for FY27. Management highlighted plans to expand the domestic business in high-margin segments and projected revenue growth of over 50% for FY27, alongside a medium-term revenue CAGR of 20-25%. The presentation detailed the company's transformation from an API player to a focused finished dosage formulation manufacturer.

Key takeaway: Ind-Swift Laboratories Limited reported stable revenue for Q3 FY26, with a 6.60% increase in Operating EBITDA and a 22.60% rise in Net Profit quarter-over-quarter. Management highlighted a strategic reset through a ₹1,650 Cr divestment of its API & CRAMS business, resulting in a net debt-free status and a focus on high-quality exports. The company operates with a revenue base of ₹550 Cr and aims to double revenue by FY29, supported by high-margin segments. The presentation detailed the company's operational efficiencies, including a 48 basis points expansion in Operating EBITDA margin. Management emphasized the importance of partnerships, particularly with Viatris, and the expansion of their Own-Brand footprint in the UAE and Central Asia. The document outlined a comprehensive market strategy and growth plans, including a focus on chronic therapies and regulatory compliance.